BWA
TGTX icon

Basecamp Wealth Advisors’s TG Therapeutics TGTX Stock Holding History

Basecamp Wealth Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.09K Buy
38
+15
+65% +$614 ﹤0.01% 1361
2026
Q1 		$764 Sell
23
-80
-78% -$2.38K ﹤0.01% 1622
2025
Q4 		$3.07K Buy
+103
New +$3.36K ﹤0.01% 1265

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Basecamp Wealth Advisors's TGTX Position: Q2 2026 in Review

Basecamp Wealth Advisors increased its TG Therapeutics (TGTX) stake by 65% in Q2 2026, buying an estimated $614 and bringing the position to 38 shares worth $2.09K. The position accounts for ﹤0.01% of the portfolio, ranked #1361.

Basecamp Wealth Advisors first reported a position in TGTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.07K in Q4 2025. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Basecamp Wealth Advisors held 38 shares of TG Therapeutics worth $2.09K as of Q2 2026.
  • Basecamp Wealth Advisors bought 15 TG Therapeutics shares in Q2 2026, an estimated $614.
  • TG Therapeutics made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1361 holding.
  • Basecamp Wealth Advisors first reported a position in TG Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Basecamp Wealth Advisors's TG Therapeutics position peaked at $3.07K in Q4 2025.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.